
Novavax Investor Profile: Sanofi Royalties, the Matrix-M Adjuvant and $627m of Cash
Novavax now earns most of its money from partners led by Sanofi. It ended September with $627m of cash and $292.1m of long-term debt; its numbers, milestones, risks and dates to…





























